UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
|
||||
(Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Sec.230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Sec.240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On January 29, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) and the minimum bid price matter is now closed. The letter was pursuant to a previous letter received on July 31, 2023 from Nasdaq the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), indicating, as previously reported, that the Company was not then in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
eFFECTOR Therapeutics, Inc. | ||||||
Date: January 30, 2024 | By: | /s/ Michael Byrnes | ||||
Name: Michael Byrnes | ||||||
Title: | Chief Financial Officer |
#*HQ<:%;Z<(W:"D&YQ"-Q,1)P]9O.*J#@37@#E_
M[@WZO1["XSI5P75.(5JR';D+8.*)M?"+03O.UR#9[YY[GM/S!BCA@26XIQ".
M@P!*(DR4_07)*^UC4AO*!DFW0\F#5":$(A0HJRHY_U=3_ 102P,$% @ _$,^6)>*NQS $P( L !?
M
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end